aspsirna0845 details

''''
ASPsiRNA information siRNA Id:aspsirna0845
siRNA Name: P2+P10_rs362273
Mismatch information Wild siRNA (As strand 3'->5'):UUCGACGACGACGUCUAGUUU
ASP-siRNA (As strand 3'->5'):UUCGACGACGAUGUCUAGUCU
Mismatch position in siRNA: C2U,U10C
Gene Information Gene Name Hungtintin (HTT)
Target Sequence (5'->3'):GTCTGCGCCCTTGTGCCCTGCCTCCA
Wild allele (5'->3'):AAGCUGCUGCUGCAGAUCAAA
Mutant allele (5'->3'):AAGCUGCUGCUACAGAUCAGA
Position of siRNA on target gene: NA
Respective Gene/Protein Resources GenBank Accession:NM_002111.7
Cytogenic location:4p16.3
Chromosomal coordinates:4:3,076,407-3,245,686
UniProt ID:Q96CV9
HUGO ID:4851
Reference SNp(RefSNP): rs362273
Disease/Mutation information Target Mutation: c.52CAG(36_39)
Matation type/variant: Microsatellite
Mutation at gene level: NG_009378.1:g.5197CAG(36_39)
Pathogenic status of mutation: Pathogenic
Disease:Huntington disease (HD)
Clinical Resources ClinVar ID:31916
KEGG disease ID:H00059
OMIM ID: 143100
COSMIC: HTT
DECIPHER: HTT
GeneTests: HTT
ASP siRNA details Mutant allele (5'->3'): AAGCUGCUGCUACAGAUCAGA
ASP-siRNA (As strand 3'->5'):UUCGACGACGAUGUCUAGUCU
Percentage efficacy of ASP-siRNA for mutant allele:NA
Wild allele (5'->3'): AAGCUGCUGCUGCAGAUCAAA
ASP-siRNA (As strand 3'->5'):UUCGACGACGAUGUCUAGUCU
Percentage efficacy of ASP-siRNA for wild allele:NA
Relative difference:NA
Wild siRNA details Wild allele (5'->3'): AAGCUGCUGCUGCAGAUCAAA
Wild siRNA (As strand 3'->5'):UUCGACGACGACGUCUAGUUU
Percentage efficacy of wild siRNA for wild allele:40
Wild allele (5'->3'): AAGCUGCUGCUGCAGAUCAAA
ASP-siRNA (As strand 3'->5'):UUCGACGACGAUGUCUAGUCU
Percentage efficacy of Wild sirna for mutant allele:12
Relative difference :28
General information Mismatch incorporated in siRNA/Target:siRNA
Cell-line used: HeLa
Experimental technique used: Dual luciferase reporter assay
Transfection method: Lipofectamine 2000
siRNA expression method: Invitrogen
Post-transfection duration: 48 hours
Concentration used:20nM
Reference:19361997
Delivery method:Transfection
Article title:Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
Authors:Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M, Landwehrmeyer B, Vonsattel JP, Zamore PD, Aronin N.
Journal Reference:Curr Biol. 2009 May 12;19(9):774-8. doi: 10.1016/j.cub.2009.03.030. Epub 2009 Apr 9.